

Hypermethylation-associated Inactivation of $p14^{ARF}$ Is Independent of $p16^{INK4a}$ Methylation and $p53$ Mutational Status¹

Manel Esteller, Silvia Tortola, Minoru Toyota, Gabriel Capella, Miguel Angel Peinado, Stephen B. Baylin, and James G. Herman²

The Johns Hopkins Oncology Center, Baltimore, Maryland 21231 [M. E., M. T., S. B. B., J. G. H.]; Laboratori d'Investigacio Gastrointestinal, Hospital de la Santa Creu i Sant Pau, Barcelona, 08025 Spain [G. C.]; and Institut de Recerca Oncologica, Hospital Duran i Reynals, Barcelona, 08907 Spain [S. T., M. A. P.]

ABSTRACT

The $INK4a/ARF$ locus encodes two cell cycle-regulatory proteins, $p16^{INK4a}$ and $p14^{ARF}$, which share an exon using different reading frames. $p14^{ARF}$ antagonizes $MDM2$ -dependent $p53$ degradation. However, no point mutations in $p14^{ARF}$ not altering $p16^{INK4a}$ have been described in primary tumors. We report that $p14^{ARF}$ is epigenetically inactivated in several colorectal cell lines, and its expression is restored by treatment with demethylating agents. In primary colorectal carcinomas, $p14^{ARF}$ promoter hypermethylation was found in 31 of 110 (28%) of the tumors and observed in 13 of 41 (32%) colorectal adenomas but was not present in any normal tissues. $p14^{ARF}$ methylation appears in the context of an adjacent unmethylated $p16^{INK4a}$ promoter in 16 of 31 (52%) of the carcinomas methylated at $p14^{ARF}$. Although $p14^{ARF}$ hypermethylation was slightly overrepresented in tumors with wild-type $p53$ compared to tumors harboring $p53$ mutations [19 of 55 (34%) versus 12 of 55 (22%)], this difference did not reach statistical significance. $p14^{ARF}$ aberrant methylation was not related to the presence of $K-ras$ mutations. Our results demonstrate that $p14^{ARF}$ promoter hypermethylation is frequent in colorectal cancer and occurs independently of the $p16^{INK4a}$ methylation status and only marginally in relation to the $p53$ mutational status.

INTRODUCTION

Disruption of the $p53$ and Rb ³ tumor suppressor pathways is a fundamental trend of most human cancer cells (1). In tumorigenesis, loss of Rb function can occur by direct inactivation of the Rb gene itself through mutation, sequestration of the Rb protein by viral oncoproteins, or promoter hypermethylation or by deregulation of the genes controlling Rb phosphorylation status (2). These last alterations include cyclin D1 gene amplification, $CDK4$ activating mutations, and also gene amplification and inactivation of the inhibitors of $CDK4$, the $INK4$ family (composed of $p15^{INK4b}$, $p16^{INK4a}$, $p18^{INK4c}$, and $p19^{INK4d}$; Refs. 1 and 3). The $p16^{INK4a}$ gene was implicated as a tumor suppressor gene by its frequent mutation, deletion, or promoter hypermethylation in a variety of human tumors (1, 4, 5). In addition, $p16^{INK4a}$ germ-line mutations have been associated with familial melanoma (6). Recently, it was demonstrated that a portion of the $p16^{INK4a}$ gene has the capacity to encode a second product, murine $p19^{ARF}$ (7). $p19^{ARF}$, or human $p14^{ARF}$, has a unique first exon (denominated exon 1 β), located approximately 20 kb centromeric to the first exon of $p16^{INK4a}$ (denoted as exon 1 α). Under the control of its

own promoter, exon 1 β splices into exon 2 of $INK4a$ in an alternative reading frame, producing a different protein than $p16^{INK4a}$ (1, 3, 7, 8).

$p19^{ARF}$ overexpression induces G₁- and G₂-phase arrest through a $p16^{INK4a}$ -independent mechanism (9). Furthermore, the $p19^{ARF}$ -mediated cell cycle arrest seems to be abolished in mouse embryo fibroblasts lacking functional $p53$ (8). Recent work suggests that $p19^{ARF}$ and $p14^{ARF}$ interact *in vivo* with the $MDM2$ protein, neutralizing $MDM2$ -mediated degradation of $p53$ (10–13). Thus, theoretically, inactivation of $p14^{ARF}$ would then be predicted to decrease the frequency for concomitant $p53$ mutations. $p19^{ARF}$ binds to $MDM2$ through its NH₂ terminus end, which encodes exon 1 β (13). $p19^{ARF}$ -specific null mice carrying a disrupted exon 1 β are cancer prone at an early age (8), but no human point mutations in exon 1 β have been reported. Interestingly, exon 1 β -specific deletions have been described in melanoma cell lines (14), and $p14^{ARF}$ genomic alterations are found in a majority of T-cell acute lymphocytic leukemias (15). However, to date, most of the functional studies of $p14^{ARF}$ have involved murine systems, and little is known about the putative $p14^{ARF}$ function as a tumor suppressor gene in humans. Recently, the human $p14^{ARF}$ promoter has been cloned and contains a CpG island that is aberrantly methylated in colorectal cancer cell lines (16). Hypermethylation of normally unmethylated CpG islands in the promoter regions of tumor suppressor and DNA repair genes, including $p16^{INK4a}$, $E-cadherin$, $hMLH1$, $GSTP1$, and $MGMT$ (4, 17–20), correlates with loss of transcription. Thus, promoter hypermethylation could be a mechanism for $p14^{ARF}$ inactivation in human tumors. In addition, methylation of $p16^{INK4a}$ and $p15^{INK4b}$ can occur with more tumor-specific patterns than found for homozygous deletions involving the entire 9p region encompassing these genes (21).

In the present study, we studied CpG island promoter methylation of the human $p14^{ARF}$ gene in cancer cell lines and more than 100 primary colorectal carcinomas. Colorectal tumors were chosen because homozygous deletions of the $INK4a/ARF$ locus are not present in this tumor type (22), and colorectal carcinoma has well-characterized mutational inactivation of $p53$, thus allowing us to examine the relationship to $p53$ mutations. Our results demonstrate that $p14^{ARF}$ can be silenced by promoter hypermethylation in colorectal cancer cell lines. In the primary colorectal tumors, $p14^{ARF}$ is aberrantly methylated in approximately a quarter of the neoplasms studied, and this methylation represents an event independent of the $p16^{INK4a}$ methylation status. Furthermore, $p14^{ARF}$ hypermethylation, although more frequent in tumors with wild-type $p53$, is also observed in those cancers with $p53$ mutations.

MATERIALS AND METHODS

MSP. DNA methylation patterns in the CpG islands of the $p14^{ARF}$ gene were determined by MSP (23). MSP distinguishes unmethylated from methylated alleles in a given gene based on sequence changes produced after bisulfite treatment of DNA, which converts unmethylated (but not methylated) cytosines to uracil, and subsequent PCR using primers designed for either methylated or unmethylated DNA (23). The primer sequences designed for $p14^{ARF}$ spanned six CpGs within the 5' region of the gene. Primer sequences of $p14^{ARF}$ for the unmethylated reaction were 5'-TTTTTGGTGTTA-

Received 6/21/99; accepted 10/27/99.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported in part by NIH Grant CA54396 and Grants from Fondo de Investigacion Sanitaria and Comision Interministerial de Ciencia y Tecnologia. M. E. is a recipient of a Spanish Ministerio de Educacion y Cultura Award. J. G. H. is a Valvano Foundation Scholar. S. B. B. and J. G. H. receive research funding and are entitled to sales royalties from ONCOR, which is developing products related to the research described in this article. The terms of this arrangement have been reviewed and approved by The Johns Hopkins University in accordance with its conflict of interest policies.

² To whom requests for reprints should be addressed, at Tumor Biology, The Johns Hopkins Oncology Center, 424 North Bond Street, Baltimore, MD 21231. Phone: (410) 955-8506; Fax: (410) 614-9884; E-mail: hermanji@jhmi.edu.

³ The abbreviations used are: Rb , retinoblastoma; MSP, methylation-specific PCR; RT-PCR, reverse transcription-PCR; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

AAGGGTGGTGTAGT-3' (sense) and 5'-CACAAAAACCCCTCACTCA-CAACAA-3' (antisense), which amplify a 132-bp product, and primer sequences of *p14^{ARF}* for the methylated reaction were 5'-GTGTTAAAGGGCGGCG-TAGC-3' (sense) and 5'-AAAACCCCTACTCGCGACGA-3' (antisense), which amplify a 122-bp product. The 5' position of the sense unmethylated and methylated primers corresponds to bp 195 and 201 of GenBank sequence number L41934. Both antisense primers originate from bp 303 of this sequence. The annealing temperature for both the unmethylated and methylated reactions was 60°C. Placental DNA treated *in vitro* with *SssI* methyltransferase was used as a positive control for methylated alleles. DNA from normal lymphocytes was used as a negative control for methylated genes. Ten μ l of each PCR reaction were loaded directly onto nondenaturing 6% polyacrylamide gels, stained with ethidium bromide, and visualized under UV illumination. DNA methylation patterns in the 5'-CpG island of *p16^{INK4a}* were determined by MSP as described previously (23).

RT-PCR. RT-PCR was performed as described previously (21), using 3 μ g of total cellular RNA to generate cDNA. This cDNA (100 ng) was amplified by PCR with primers for exon 1 β (5'-GGTTTTCTGGTTCACATCCCGCG-3') and exon 2 (5'-CAGGAAGCCCTCCCGGCAGC-3') of *p14^{ARF}*, which amplify a 254-bp product spanning sequence 204–437 from GenBank accession number S78535. RT-PCR for GAPDH served as a positive control. Ten μ l of each PCR reaction were loaded directly onto nondenaturing 6% polyacrylamide gels, stained with ethidium bromide, and visualized under UV illumination.

Detection of K-ras and p53 Mutations. Mutations at codons 12 and 13 of the *K-ras* gene were detected and characterized by a RFLP/PCR approach (24). *p53* mutations in exons 4–9 were analyzed by single-strand conformational polymorphism analysis. Briefly, a first PCR was performed using primers 12979U (GCTGCCGTGTCCAGTTGCT) and 14875D (AGGCATCACTGCCCTGAT). The resulting 1897-bp fragment was then used as a template to separately amplify a fragment of 410 bp including exons 5 and 6 [with primers 13054U (TACTCCCTGCCCTCAACAAG) and 13463D (CTCCTCCAGAGACCCAGT)] and a fragment of 622 bp including exons 7 and 8 [with primers 13966U (CTGGCCTCATCTTGGGCCTG) and 14587D (CTCGTTAGTGCTCCCTGGG)]. These two fragments were then digested with restriction enzyme *HpaII*, and the resulting fragments were run on a 6% polyacrylamide gel without glycerol (0.2 h at 30 W and 5–6 h at 6 W) and with 10% glycerol (0.2 h at 30 W and 13–14 h at 6 W) to detect mobility shifts. Mutations were confirmed by direct cycle sequencing of the PCR products using the AmpliCycle Sequencing Kit (Perkin-Elmer, Branchburg, NJ). Exons 4 and 9 were only analyzed on those samples negative for mutations in exons 5–8. Exon 4 was amplified directly from DNA using primers 12019U (GTC-CCCCTTGCCGTCCCAAG) and 12349D (TACGGCAGGCATTGAA-GTC). The resulting 331-bp fragment was run without previous digestion on a 6% polyacrylamide/10% glycerol gel for 0.2 h at 30 W and 19 h at 6 W. To analyze exon 9, a fragment of 788 bp including exons 7–9 was amplified with primers 13966U (CTGGCCTCATCTTGGGCCTG) and 14753D (CTGAAG-GGTGAAATATTCTCC) and digested with *HhaI* to produce two fragments of 548 and 240 bp, the latter of which contained exon 9.

RESULTS

Promoter Hypermethylation and Expression of *p14^{ARF}* in Cancer Cell Lines. Structurally, *p14^{ARF}* is a candidate for hypermethylation-associated inactivation because a 5'-CpG island is located around the transcription start site (16). The region chosen for the MSP analysis spans the area of greatest CpG density studied recently for methylation changes in several cell lines (16). Normal lymphocytes, colon, breast, endometrium, and lung were found completely unmethylated at the *p14^{ARF}* promoter (Fig. 1A). Normal kidney and liver were also unmethylated at *p14^{ARF}*. We also examined 16 cancer cell lines derived from these tissues. *p14^{ARF}* was fully methylated in four (25%) colorectal carcinoma cell lines (SW48, RKO, DLD-1, and LoVo; Fig. 1B). Among these, expression of the *p14^{ARF}* transcript by RT-PCR was assessed in LoVo and DLD-1, both of which lack *p14^{ARF}* expression (Fig. 1C). Treatment of these cell lines with the demethylating agent 5-aza-2'-deoxycytidine restored the expression

of the transcript in both cases (Fig. 1C). These results agree with those recently reported by Robertson *et al.* (16), although in that case, the colorectal cancer cell line HCT-15, which is isogenic to the DLD-1 cell line (25), was used. The colorectal cancer cell line RKO methylated at *p14^{ARF}* showed a low level of expression but demonstrated an increase in RNA after the treatment with 5-aza-2'-deoxycytidine. A similar phenomenon has been described previously in the case of the colorectal cancer cell line SW48 (16), which was also methylated at *p14^{ARF}* in our study. The colorectal cancer cell lines SW1417, SK-CO1, LS180T, and HT-29 were partially methylated, and *p14^{ARF}* expression was demonstrated in the last one (Fig. 1C). Normal lymphocytes and the unmethylated colorectal cell line SW480 and the unmethylated leukemia cell line HL-60 demonstrated expression of the *p14^{ARF}* transcript (Fig. 1C).

The proposed role of *p14^{ARF}* in modulating *p53-MDM2* function would predict the diminishing need of *p53* mutations in those tumors or cell lines with *p14^{ARF}* promoter hypermethylation, assuming that only one "hit" in the same pathway would be necessary in the transforming process. In this series of cancer cell lines, cell lines fully methylated at *p14^{ARF}* (LoVo, DLD-1, SW48, and RKO) were more frequently found to have an intact *p53* [three of four cell lines (75%), with the exception DLD-1]. Among cell lines with an unmethylated promoter, including colorectal cells, non-small cell lung cancer, and leukemia (SW480, HCT116, SW837, COLO205, H157, H1618, U1752, and HL-60), only one (HCT116) had a wild-type *p53*. Thus, most cancer cell lines methylated at *p14^{ARF}* are wild-type *p53*, and those unmethylated have a mutant *p53*, but this difference did not reach statistical significance (Fisher's exact test, $P = 0.07$).

Promoter Hypermethylation of *p14^{ARF}* in Primary Colorectal Carcinomas. DNA obtained from 110 primary colorectal carcinomas was subjected to *p14^{ARF}* promoter methylation study using MSP. Among all of the colorectal tumors studied, *p14^{ARF}* promoter hypermethylation was present in 31 of 110 (28%) samples (Fig. 1D). In 32 patients from whom normal adjacent mucosa DNA was available, no methylation of the *p14^{ARF}* promoter was observed in any case (an example is shown in Fig. 1A). Thus, the methylation observed in the colorectal cancers and cell lines is a tumor-specific change. Abnormal methylation of the *p14^{ARF}* promoter region in the colorectal carcinomas was not associated with significant differences of gender, age of onset, clinical status, Duke's stage, DNA ploidy, or the presence of residual disease. When the samples were decoded for their *p53* status, *p14^{ARF}* was hypermethylated in 19 of 55 (34%) colorectal tumors with wild-type *p53* and in 12 of 55 (22%) tumors with a mutant *p53* (Fig. 2A). Thus, although the tumors with functional *p53* more often harbor *p14^{ARF}* epigenetic inactivation than tumors with *p53* mutations, this trend does not reach statistical significance (Fisher's exact test, $P = 0.20$) and was certainly not limited to *p53* wild-type tumors (Fig. 2A).

We also wondered whether *p14^{ARF}* promoter hypermethylation would be related to promoter hypermethylation of the adjacent gene, *p16^{INK4a}*. Aberrant methylation of *p16^{INK4a}* was assessed in the same samples analyzed for *p14^{ARF}* methylation and demonstrated in 41 of 110 (37%) of the primary colorectal carcinomas studied, a frequency similar to that described previously (Ref. 26; Fig. 1D). *p14^{ARF}* was hypermethylated in the presence of an unmethylated *p16^{INK4a}* promoter in 16 of 110 (14%) of the cases, whereas *p14^{ARF}* promoter hypermethylation was coincident with *p16^{INK4a}* promoter hypermethylation in 15 of 110 (14%) of the cases (Fig. 2B). In 26 of 110 (24%) of the cases, *p16^{INK4a}* was methylated without *p14^{ARF}* methylation (Fig. 2B). Thus, methylation at the *p14^{ARF}* and *p16^{INK4a}* promoters does not seem to be directly related (Fisher's exact test, $P = 0.28$). It has been hypothesized that mutations in exons 1–4 of *p53* may be concomitant with alterations in both *p16^{INK4a}* and *p14^{ARF}*




Fig. 1. MSP analysis of the promoter region of *p14^{ARF}* and reactivation of *p14^{ARF}* by treatment with 5'-aza-2'-deoxycytidine. The presence of a visible PCR product in *Lanes U* indicates the presence of unmethylated genes of *p14^{ARF}*; the presence of product in *Lanes M* indicates the presence of methylated genes. *In vitro* methylated DNA (*IVD*) was used as a positive control for *p14^{ARF}* promoter hypermethylation, and normal lymphocytes (*NL*) were used as a negative control for methylation. Water controls for PCR reactions are also shown. MSP of *p14^{ARF}* in normal tissues (*A*) and cancer cell lines (*B*). *C*, the pattern of expression determined by RT-PCR of the *p14^{ARF}* transcript in cancer cell lines SW480, DLD-1, DLD-1 after 5-aza-2'-deoxycytidine treatment, LoVo, LoVo after 5-aza-2'-deoxycytidine treatment, HT-29, and HL-60 and in normal lymphocytes. GAPDH expression demonstrates relatively equal amounts of initial mRNA. *D*, MSP of *p14^{ARF}* in primary colorectal carcinomas (*CRC*) of *p14^{ARF}* (*top panel*) and *p16^{INK4a}* (*bottom panel*). *CRC1* and *CRC6* are unmethylated at both genes, *CRC2* and *CRC5* are methylated only at *p16^{INK4a}*, *CRC3* is methylated only at *p14^{ARF}*, and *CRC4* is methylated at both genes. *E*, MSP of *p14^{ARF}* in colorectal adenomas. *p14^{ARF}* promoter hypermethylation is demonstrated in samples A2, A4, A5, and A7.

(27). Although we did not address this aspect specifically, in the three cases in which exon 4 mutations were found, *p16^{INK4a}* was unmethylated in all three, and *p14^{ARF}* was methylated in only one case.

Because it has been recently reported that *p19^{ARF}* (the mouse homologue of *p14^{ARF}*) is essential for the activation of *p53* in response to oncogenic *Ras* (28), we also examined the *p14^{ARF}* promoter hypermethylation in relation to the *K-ras* status of the tumor. A total of 43 of 110 (39%) primary colorectal carcinomas had a *K-ras* point mutation. The frequency of *p14^{ARF}* methylation was slightly higher in tumors with *K-ras* mutations than in those without *K-ras* mutations [15 of 43 (35%) versus 16 of 67 (24%)], but this difference was not statistically significant (Fisher's exact test, $P = 0.28$). Thus, no evident linkage between these epigenetic and genetic alterations was observed.

Promoter Hypermethylation and Expression of *p14^{ARF}* in Colorectal Adenomas. DNA obtained from 41 primary colorectal adenomas was subjected to *p14^{ARF}* promoter methylation study using MSP. Among all of the adenomas studied, *p14^{ARF}* promoter hypermethylation was present in 13 of 41 (32%) samples (Fig. 1E). We also examined the expression of *p14^{ARF}* using RT-PCR in these colorectal adenomas. Among 20 early lesions with available cDNA, 12 colorectal adenomas unmethylated at *p14^{ARF}* expressed high levels of *p14^{ARF}* mRNA, whereas 8 adenomas with *p14^{ARF}* methylation expressed no

detectable *p14^{ARF}* mRNA ($n = 7$) or very little *p14^{ARF}* mRNA ($n = 1$), demonstrating an exact correlation of transcriptional loss with *p14^{ARF}* hypermethylation (Fig. 3). The similar rate of *p14^{ARF}* methylation in adenomas and carcinomas suggests that like *p16^{INK4a}* methylation, inactivation of *p14^{ARF}* appears to be an early event in colorectal tumorigenesis.


DISCUSSION

Our study represents the first finding of a specific lesion in *p14^{ARF}*, promoter hypermethylation, in primary human tumors. In many cases, this does not affect the neighboring gene, *p16^{INK4a}*. Furthermore, our data establish that, at least in colorectal tumors, the inactivation on *p14^{ARF}* is not restricted to those neoplasms with intact *p53*. It has been postulated that due to the fact that *p53* is directly targeted in approximately 50% of human malignancies (29), other mechanisms are required to shut down the *p53* pathway in tumors with wild-type *p53*. For example, lesions in the *MDM2* gene such as amplification can lead to *MDM2* overexpression and abrogation of *p53* function. *MDM2* represses *p53* transcriptional activity and mediates the degradation of *p53* (30). However, *MDM2* gene amplification is restricted to a few tumor types (30). *p53* degradation mediated by the viral protein E6 is also limited to a minority of neoplasms (31). Another event contrib-

uting to abrogate the *p53* pathway in the cancer cell may be *p14^{ARF}* loss of function. Somatic mutations affecting exons 2 and 3 *p14^{ARF}*, shared in an alternative reading frame with *p16^{INK4a}*, have been demonstrated in tumors (1, 5), but no mutations in the specific exon 1 β of *p14^{ARF}* have been reported. *p14^{ARF}* can also be lost by homozygous deletion in several tumor types (22), but this loss also targets *p16^{INK4a}* in the vast majority of cases. However, *p14^{ARF}* has been proposed as the crucial target in T-cell acute lymphocytic leukemias and glioblastomas that exhibit 9p21 lesions (15). Recently, aberrant methylation of the *p14^{ARF}* promoter has been demonstrated in cancer cell lines (16). Our data corroborate the findings of loss of *p14^{ARF}* expression associated with CpG island methylation and its restoration by the use of demethylating agents. We now demonstrate that such hypermethylation of *p14^{ARF}* is not limited to cell lines and is not a rare event. Colorectal carcinomas were selected because these cancers do not show homozygous deletion of the 9p21 locus (22) and thus allow the separate study of *p14^{ARF}* and *p16^{INK4a}* inactivation. In addition, the considerable rate of *p53* mutations in colorectal tumors helps us to address the existence or nonexistence of a relation between *p14^{ARF}* and *p53* status.

Our results demonstrate that *p14^{ARF}* promoter hypermethylation occurs in approximately one-fourth of primary colorectal carcinomas. *p14^{ARF}* promoter hypermethylation also seems to be an early event in colorectal tumorigenesis because, like *p16^{INK4a}* methylation, it can be found in colon adenomas. When the *p14^{ARF}* promoter methylation analysis is compared with the *p53* status, we observe only a slightly decreased occurrence of *p53* mutations in those primary tumors with *p14^{ARF}* inactivation. Thus, *p14^{ARF}* and *p53* can be inactivated simultaneously in the same tumor. Such a scenario is also observed in a

A Inactivation of the *p53/p14^{ARF}* Pathway in Colorectal Tumors



B Promoter Hypermethylation in the *INK4a/ARF* Locus in Colorectal Tumors




Fig. 2. Patterns of *p14^{ARF}* promoter hypermethylation according to *p53* mutational status (A) and *p16^{INK4a}* promoter hypermethylation (B) in colorectal tumors.




Fig. 3. Pattern of expression determined by RT-PCR of the *p14^{ARF}* transcript in colorectal adenomas. The adenomas with *p14^{ARF}* promoter hypermethylation show a complete lack (A2, A7, A11, A20, A4, A5, A18) or strongly diminished (A14) *p14^{ARF}* expression. The colorectal adenomas unmethylated at *p14^{ARF}* (A1, A3, A8, A9, A10, A12, A13, A15, A16, A17, A6, A19) show high levels of the transcript. GAPDH expression demonstrates relatively equal amounts of initial mRNA.

mouse model, where tumors arising in *p19^{ARF}*^{-/-} mice can harbor *p53* mutations (8).

Finally, it is relevant to note that *p14^{ARF}* promoter hypermethylation is not dependent on *p16^{INK4a}* promoter methylation status. In our set of colorectal tumors, the most common situation is the simultaneous absence of methylation in both promoters (48%), but after this, the three possible scenarios (*p16^{INK4a}* methylated alone, *p14^{ARF}* methylated alone, and both methylated) are similarly represented. In primary colorectal carcinoma, hypermethylation of *p14^{ARF}* and *p16^{INK4a}* are independent events. In colorectal cancer cell lines, because the vast majority of cell lines are methylated at *p16^{INK4a}*, no cell line has *p14^{ARF}* methylation with an unmethylated *p16^{INK4a}* promoter. It is also interesting that the CpG island of *p15^{INK4b}*, which is located only 14 kb upstream of the *p14^{ARF}* promoter, remains unmethylated in colorectal tumors and cell lines, although it is methylated in leukemia (21). Thus, the *p14^{ARF}* promoter demonstrates selective epigenetic silencing in a subset of colorectal tumors, with a hypermethylated promoter (*p14^{ARF}*) between two unmethylated promoters (*p16^{INK4a}* and *p15^{INK4b}*) that are frequently methylated in other tumors.

In summary, our data suggest that promoter hypermethylation of *p14^{ARF}* is a relatively common and early event in colorectal tumorigenesis and is not necessarily related to the methylation status of neighbor gene *p16^{INK4a}* or restricted to tumors with intact *p53*.

ACKNOWLEDGMENTS

We thank Andrew B. Sparks and Kenneth W. Kinzler for providing cell lines for this study.

REFERENCES

- Sherr, C. J. Cancer cell cycles. *Science* (Washington DC), 276: 1672–1677, 1996.
- Weinberg, R. A. The retinoblastoma protein and cell cycle control. *Cell*, 81: 323–330, 1995.
- Chin, L., Pomerantz, J., and DePinho, R. A. The INK4a/ARF tumor suppressor: one gene-two products-two pathways. *Trends Biochem. Sci.*, 23: 291–296, 1998.
- Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. *Nat. Med.*, 1: 686–692, 1995.
- Kamb, A. Cell-cycle regulators and cancer. *Trends Genet.*, 11: 136–140, 1995.
- Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H., Tucker, M. A., and Dracopoli, N. C. Germline p16 mutations in familial adenoma. *Nat. Genet.*, 8: 15–21, 1994.
- Quelle, D. E., Zindy, F., Ashmun, R. A., and Scherr, C. J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. *Cell*, 83: 993–1000, 1995.
- Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., and Sherr, C. J. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19^{ARF}. *Cell*, 91: 649–659, 1997.
- Sherr, C. J. Tumor surveillance via the ARF-p53 pathway. *Genes Dev.*, 12: 2434–2442, 1998.

10. Pomerantz, J., Schreiber-Agus, N., Liegeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H. W., Cordon-Cardo, C., and DePino, R. A. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. *Cell*, *92*: 713–723, 1998.
11. Zhang, Y., Xiong, Y., and Yarbrough, W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. *Cell*, *92*: 725–734, 1998.
12. Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., and Sherr, C. J. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. *Proc. Natl. Acad. Sci. USA*, *95*: 8292–8297, 1998.
13. Stott, F. J., Bates, S., James, M. C., McConnell, B. B., Starborg, M., Brookes, S., Palmero, I., Ryan, K., Hara, E., Vousden, K. H., and Peters, G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. *EMBO J.*, *17*: 5001–5014, 1998.
14. Larsen, C. J. p16^{INK4a}: a gene with dual capacity to encode unrelated proteins that inhibit cell cycle progression. *Oncogene*, *12*: 2041–2044, 1996.
15. Gardie, B., Cayuela, J. M., Martini, S., and Sigaux, F. Genomic alterations of the p19^{ARF} encoding exons in T-cell acute lymphoblastic leukemia. *Blood*, *91*: 1016–1020, 1998.
16. Robertson, K. D., and Jones, P. A. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. *Mol. Cell. Biol.*, *18*: 6457–6473, 1998.
17. Baylin, S. B., Herman, J. G., Graff, J. R., Vertino, P. M., and Issa, J. P. Alterations in DNA methylation: a fundamental aspect of neoplasia. *Adv. Cancer Res.*, *72*: 141–196, 1998.
18. Herman, J. G., Umar, A., Polyak, K., Graff, J. R., Ahuja, N., Issa, J. P., Markowitz, S., Willson, J. K., Hamilton, S. R., Kinzler, K. W., Kane, M. F., Kolodner, R. D., Vogelstein, B., Kunkel, T. A., and Baylin, S. B. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. *Proc. Natl. Acad. Sci. USA*, *95*: 6870–6875, 1998.
19. Esteller, M., Corn, P. G., Urena, J. M., Gabrielson, E., Baylin, S. B., and Herman, J. G. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. *Cancer Res.*, *58*: 4515–4518, 1998.
20. Esteller, M., Hamilton, S. R., Burger, P. C., Baylin, S. B., and Herman, J. G. Inactivation of the DNA repair gene *O*⁶-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. *Cancer Res.*, *59*: 793–797, 1999.
21. Herman, J. G., Jen, J., Merlo, A., and Baylin, S. B. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15^{INK4B}. *Cancer Res.*, *56*: 722–727, 1996.
22. Cairns, P., Polascik, T. J., Eby, Y., Tokino, K., Califano, J., Merlo, A., Mao, L., Herath, J., Jenkins, R., Westra, W., Rutter, J. L., Buckler, A., Gabrielson, E., Tockman, M., Cho, K. R., Hedrick, L., Bova, G. S., Isaacs, W., Koch, W., Schwab, D., and Sidransky, D. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. *Nat. Genet.*, *11*: 210–212, 1995.
23. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. Methylation specific PCR: a novel PCR assay for methylation status of CpG islands. *Proc. Natl. Acad. Sci. USA*, *93*: 9821–9826, 1996.
24. Capella, G., Cronauer-Mitra, S., Peinado, M. A., and Perucho, M. Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. *Environ. Health Persp.*, *93*: 125–131, 1991.
25. Vermeulen, S. J., Chen, T. R., Speleman, F., Nollet, F., Van Roy, F. M., and Mareel, M. M. Did the four human cancer cell lines DLD-1, HCT-15, HCT-8, and HRT-18 originate from one and the same patient? *Cancer Genet. Cytogenet.*, *107*: 76–79, 1998.
26. Herman, J. G., Merlo, A., Mao, L., Lapidus, R. G., Issa, J. P., Davidson, N. E., Sidransky, D., and Baylin, S. B. Inactivation of the *CDKN2/p16/MTS1* gene is frequently associated with aberrant DNA methylation in all common human cancers. *Cancer Res.*, *55*: 4525–4530, 1995.
27. Markl, I. D., and Jones, P. A. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer. *Cancer Res.*, *58*: 5348–5353, 1998.
28. Palmero, I., Pantoja, C., and Serrano, M. p19^{ARF} links the tumour suppressor p53 to Ras. *Nature (Lond.)*, *395*: 125–126, 1998.
29. Hainaut, P., Soussi, T., Shomer, B., Hollstein, M., Greenblatt, M., Hovig, E., Harris, C. C., and Montesano, R. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. *Nucleic Acids Res.*, *25*: 151–157, 1997.
30. Prives, C. Signaling to p53: breaking the MDM2–p53 circuit. *Cell*, *95*: 5–8, 1998.
31. Rapp, L., and Chen, J. J. The papillomavirus E6 proteins. *Biochim. Biophys. Acta*, *1378*: F1–F19, 1998.

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

Hypermethylation-associated Inactivation of $p14^{ARF}$ Is Independent of $p16^{INK4a}$ Methylation and $p53$ Mutational Status

Manel Esteller, Silvia Tortola, Minoru Toyota, et al.

Cancer Res 2000;60:129-133.

Updated version Access the most recent version of this article at:
<http://cancerres.aacrjournals.org/content/60/1/129>

Cited articles This article cites 30 articles, 13 of which you can access for free at:
<http://cancerres.aacrjournals.org/content/60/1/129.full#ref-list-1>

Citing articles This article has been cited by 88 HighWire-hosted articles. Access the articles at:
<http://cancerres.aacrjournals.org/content/60/1/129.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerres.aacrjournals.org/content/60/1/129>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.